Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Other Non-Current Liabilities (2019 - 2025)

Historic Other Non-Current Liabilities for Summit Therapeutics (SMMT) over the last 7 years, with Q3 2025 value amounting to $1.8 million.

  • Summit Therapeutics' Other Non-Current Liabilities rose 664.34% to $1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.8 million, marking a year-over-year increase of 664.34%. This contributed to the annual value of $1.6 million for FY2024, which is 435.34% up from last year.
  • As of Q3 2025, Summit Therapeutics' Other Non-Current Liabilities stood at $1.8 million, which was up 664.34% from $1.8 million recorded in Q2 2025.
  • Summit Therapeutics' Other Non-Current Liabilities' 5-year high stood at $3.3 million during Q1 2024, with a 5-year trough of $1.4 million in Q4 2022.
  • Moreover, its 5-year median value for Other Non-Current Liabilities was $1.8 million (2025), whereas its average is $2.1 million.
  • As far as peak fluctuations go, Summit Therapeutics' Other Non-Current Liabilities plummeted by 4852.31% in 2022, and later soared by 12349.76% in 2024.
  • Summit Therapeutics' Other Non-Current Liabilities (Quarter) stood at $2.8 million in 2021, then plummeted by 48.52% to $1.4 million in 2022, then grew by 9.31% to $1.6 million in 2023, then grew by 4.35% to $1.6 million in 2024, then increased by 12.27% to $1.8 million in 2025.
  • Its last three reported values are $1.8 million in Q3 2025, $1.8 million for Q2 2025, and $1.7 million during Q1 2025.